Hyperlipidemia
MONDO:0021187Also known as: hyperlipidemia, hyperlipidemia (disease), hyperlipemia, hyperlipemias, lipemia, lipemias, lipidemia, lipidemias
360 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New study aims to tame cholesterol side effect of lung cancer drug
Disease control Not yet recruitingThis study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New team approach aims to simplify care for heart and kidney health
Disease control Not yet recruitingThis study tests a 6-month program where patients work with a pharmacist and their primary care doctor to make shared decisions about medications and lifestyle. The goal is to see if this team-based approach improves heart and kidney health scores and medication adherence. The st…
Phase: EARLY_PHASE1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New injection aims to tackle high cholesterol in early human trial
Disease control Not yet recruitingThis early-stage trial tests a single injection of MWX205 in 37 adults with high cholesterol or blood fats (dyslipidemia). Researchers will check if the drug is safe, how the body processes it, and how it affects cholesterol levels compared to a placebo. The goal is to find the r…
Phase: PHASE1 • Sponsor: Shanghai Minwei Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for stubborn high cholesterol: pemafibrate trial launches
Disease control Not yet recruitingThis study tests a drug called pemafibrate in 120 adults with high cholesterol that remains high even after taking statins. Participants will take either a low or higher dose of pemafibrate or a placebo pill daily for 12 weeks. The goal is to see if pemafibrate can safely lower c…
Phase: PHASE4 • Sponsor: Kowa Company, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo pill aims to supercharge cholesterol lowering
Disease control Not yet recruitingThis Phase 3 trial tests whether a new combination pill containing laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone. About 200 adults with high cholesterol and a history of heart disease or high risk will take either the combo or a placebo plus …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill could help millions with stubborn high cholesterol
Disease control Not yet recruitingThis phase 3 trial tests bempedoic acid, a daily pill, in 222 adults with high cholesterol that statins alone can't control. Participants take the drug or a placebo for 12 weeks while staying on their usual cholesterol meds. The main goal is to see how much LDL ('bad') cholestero…
Phase: PHASE3 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cholesterol combo pill aims to slash bad cholesterol without prior meds
Disease control Not yet recruitingThis study tests a new pill that combines two drugs (laroprovstat and rosuvastatin) to lower LDL or 'bad' cholesterol. About 600 adults with high cholesterol who have never taken cholesterol-lowering medication will receive either the combination, one of the drugs alone, or a pla…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New shot could help teens with rare, severe high cholesterol
Disease control Not yet recruitingThis study tests a new drug called zodasiran in 12 teens aged 12 to 17 with homozygous familial hypercholesterolemia, a rare genetic condition causing very high cholesterol. The drug is given as a shot under the skin. The main goal is to see if it safely lowers bad cholesterol af…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a common cholesterol pill flush out 'forever chemicals' from veterans' bodies?
Disease control Not yet recruitingThis study tests whether a drug called colesevelam, normally used for high cholesterol, can help lower levels of PFAS (often called 'forever chemicals') in the blood of veterans. About 50 veterans with high PFAS levels will receive either the drug or a placebo for a period, and r…
Phase: PHASE2 • Sponsor: University of Rhode Island • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot aims to slash Sky-High cholesterol in rare genetic disease
Disease control Not yet recruitingThis Phase 2 trial tests an injection called SYH2070 in 18 Chinese adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants receive the drug for 48 weeks to see if it safely lowers their LDL cholesterol…
Phase: PHASE2 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Heart-Health drug combo tested to ward off dementia in High-Risk group
Disease control Not yet recruitingThis small pilot study will test a pharmacist-led program to control high blood pressure and cholesterol in 10 people aged 50-75 who carry the APOE ε4 gene, a major risk factor for Alzheimer's. Participants will take specific medications for six months to see if managing these he…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New injection targets hidden heart risk in early trial
Disease control Not yet recruitingThis early-stage study tests a single dose of BSA204, an experimental injection, in 40 Chinese adults with borderline high lipoprotein(a) – a fatty substance linked to heart disease. The main goal is to check safety and side effects, while also measuring changes in cholesterol le…
Phase: PHASE1 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Triple cholesterol punch: could three drugs beat two after a heart attack?
Disease control Not yet recruitingThis study compares a three-drug combination (atorvastatin, ezetimibe, and bempedoic acid) against the usual two-drug therapy for lowering LDL cholesterol in people who have had a heart attack or unstable angina. About 120 adults will take either the triple or dual therapy for 3 …
Phase: PHASE4 • Sponsor: Punjab Institute of Cardology • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New shot aims to lower high blood fats in early human test
Disease control Not yet recruitingThis early-stage study tests a new medicine called ISH0688, given as a shot under the skin, for people with high triglycerides (a type of blood fat). The study will involve 104 healthy volunteers and people with high triglycerides to check the drug's safety and how the body proce…
Phase: PHASE1 • Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New program aims to protect cancer Patients' hearts during treatment
Disease control Not yet recruitingThis study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot takes aim at genetic high cholesterol
Disease control Not yet recruitingThis Phase 3 trial tests an injection called SYH2053 for people with heterozygous familial hypercholesterolemia (HeFH), a genetic condition causing very high LDL cholesterol. About 135 adults on stable statin therapy will receive either the drug or a placebo. The main goal is to …
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gene-Editing shot takes aim at inherited high cholesterol
Disease control Not yet recruitingThis early study tests a new injection called ART002g1 in 24 adults with a genetic form of high cholesterol (HeFH). The injection uses gene editing to lower a protein that raises cholesterol levels. The main goal is to check safety and how well the drug works at reducing choleste…
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame inherited high cholesterol
Disease control Not yet recruitingThis Phase III trial tests QLC7401, a new RNA-based drug, in 120 adults with heterozygous familial hypercholesterolemia (a genetic condition causing very high cholesterol). Participants already on cholesterol medication will receive either QLC7401 or a placebo injection. The stud…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cholesterol drug QLC7401 enters final testing phase
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called QLC7401 in about 780 adults with high cholesterol that remains high despite standard therapy. Participants will receive either QLC7401 or a placebo, added to their current cholesterol medications. The main goal is to see if QLC7401 can s…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New gene-silencing drug aims to lower bad cholesterol without permanent DNA changes
Disease control Not yet recruitingThis early-stage study tests STX-1150, a new medicine that temporarily turns off a gene (PCSK9) in the liver to lower bad cholesterol (LDL-C). It does not change your DNA. Up to 64 adults with high LDL-C will receive one or more doses and be followed for a year. The main goal is …
Phase: PHASE1 • Sponsor: Monash University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New triple drug combo aims to slash cholesterol after heart attacks
Disease control Not yet recruitingThis study tests whether giving a triple combination of cholesterol-lowering drugs (a high-intensity statin, ezetimibe, and bempedoic acid) right after a heart attack works better than usual care. About 600 adults hospitalized for a heart attack will be randomly assigned to the t…
Phase: PHASE3 • Sponsor: Heart Care Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Specialist dream team takes on heart disease and diabetes
Disease control Not yet recruitingThis study tests whether a special clinic where heart, kidney, diabetes, and liver doctors work together can help people with type 2 diabetes and heart disease get better control of their blood pressure and cholesterol. About 150 adults will be randomly assigned to either usual c…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New shot could help lower stubborn high cholesterol
Disease control Not yet recruitingThis Phase 3 trial tests an injection called SYH2053 for people with high cholesterol that isn't controlled by standard pills. About 900 adults aged 18-75 will receive either the drug or a placebo, on top of their usual cholesterol medication. The main goal is to see if SYH2053 s…
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New Omega-3 pill could boost heart health better than standard fish oil
Disease control Not yet recruitingThis study tests whether a new omega-3 supplement called Ruby-O, made from phospholipids, raises omega-3 levels in the blood more effectively than standard omega-3 supplements. About 105 adults with mixed dyslipidemia (abnormal blood fats) who are already on statin therapy will t…
Phase: NA • Sponsor: Fundación del Caribe para la Investigación Biomédica • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New shot could help when statins Aren't enough for high cholesterol
Disease control Not yet recruitingThis study tests a new injectable drug called DNV001 in about 120 adults with high cholesterol that isn't well controlled by statins. Participants will receive different doses of the drug or a placebo as a shot under the skin, while continuing their usual statin pills. The main g…
Phase: PHASE2 • Sponsor: Hangzhou Dinovate Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
AI family doctor app aims to keep heart patients healthy after surgery
Disease control Not yet recruitingThis study tests whether an AI-powered app called 'Smart family doctor' can help people who have had heart surgery (bypass or stent) better control their blood pressure, blood sugar, and cholesterol. About 951 participants from 10-20 hospitals will use the app for personalized he…
Phase: NA • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cholesterol drug candidate enters early human testing
Disease control Not yet recruitingThis early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. …
Phase: PHASE1 • Sponsor: Addpharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a simple supplement tame a stubborn heart risk?
Disease control Not yet recruitingThis pilot study tests whether a natural supplement called 2-HOBA can reduce harmful oxidized fats in people with high lipoprotein(a), a genetic risk factor for heart disease. Ten adults with elevated Lp(a) will take 2-HOBA capsules for 6 weeks. Researchers will measure changes i…
Phase: NA • Sponsor: The Miriam Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Blow into this tube: a new breath test may spot high cholesterol early
Diagnosis Not yet recruitingThis study is testing a new, non-invasive way to screen for high cholesterol using a person's breath. Researchers will collect exhaled breath samples from 280 healthy adults and those with high cholesterol. They will analyze the breath for unique chemical patterns to see if the t…
Sponsor: Beijing Anzhen Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Video game workouts tested for kids with high cholesterol
Symptom relief Not yet recruitingThis study tests whether an 8-week virtual reality exercise program using the Microsoft Kinect can improve body composition, balance, and daily participation in 32 children aged 8-14 with hyperlipidemia (high cholesterol). The program includes game-based activities like boat navi…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Can a simple WhatsApp message save lives? chile tests new screening nudge
Knowledge-focused Not yet recruitingThis study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…
Phase: NA • Sponsor: University of Chile • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Which contact method best warns families of hidden cholesterol danger?
Knowledge-focused Not yet recruitingThis study compares two approaches to notify relatives of people diagnosed with familial hypercholesterolemia (FH), a genetic condition causing very high cholesterol. One method lets patients share information themselves; the other has the study team contact relatives directly. R…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Are cholesterol patients getting the right care? new study aims to find out
Knowledge-focused Not yet recruitingThis study will follow about 2,500 adults in Italy who have high cholesterol and are at high risk for heart problems. Researchers want to see if their current treatments match official guidelines and how well their cholesterol is controlled over one year. The goal is to find gaps…
Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Italian study to track Real-World use of Next-Gen cholesterol drugs
Knowledge-focused Not yet recruitingThis study will look at how consistently nearly 6,000 adults in Italy take three newer cholesterol-lowering drugs (inclisiran, evolocumab, and alirocumab) over the long term. Researchers will analyze prescription records to measure adherence and persistence in everyday medical pr…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
100,000 seniors studied to uncover links between diabetes, heart risk, and kidney disease
Knowledge-focused Not yet recruitingThis observational study will follow 100,000 elderly Chinese adults (age 65+) to see how metabolic conditions like diabetes, high blood pressure, and high cholesterol impact the development and progression of chronic kidney disease (CKD). Participants will provide blood and urine…
Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Cholesterol drug showdown: which one do patients actually take?
Knowledge-focused Not yet recruitingThis study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treat…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Digital nudge: could a letter save your heart?
Knowledge-focused Not yet recruitingThis study tests whether sending an electronic letter to people with heart disease and high cholesterol encourages them to get their cholesterol checked. Researchers will compare those who receive the letter to those who don't, using national health records to track results. The …
Phase: NA • Sponsor: Tor Biering-Sørensen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
30,000 blood samples could revolutionize rapid disease testing
Knowledge-focused Not yet recruitingThis study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…
Sponsor: LumiraDx UK Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo tested for safety in healthy volunteers
Knowledge-focused Not yet recruitingThis early-stage study will test three experimental drugs (AD-231A, AD-231B, and AD-231C) in 55 healthy adults to see how they interact in the body and if they are safe. The drugs are being developed for high blood pressure and high cholesterol. Participants must be between 19 an…
Phase: PHASE1 • Sponsor: Addpharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Ancient wisdom meets AI: new system aims to tame Triple-Threat chronic diseases
Knowledge-focused Not yet recruitingThis study aims to create an AI system that combines Traditional Chinese Medicine (TCM) body type data with modern technology to give personalized health advice. Researchers will enroll 195 adults who have all three conditions: high blood pressure, high blood sugar, and high chol…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Health coaches to the rescue: can community workers help patients manage multiple illnesses?
Knowledge-focused Not yet recruitingThis study will see if community health workers (CHWs) can help people with two or more chronic conditions like diabetes, high blood pressure, or heart disease better manage their health. About 300 adults who are medically underserved will work with a CHW to create a personal hea…
Phase: NA • Sponsor: Meharry Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Massive diabetes registry aims to unlock secrets of metabolic disease
Knowledge-focused Not yet recruitingThis 10-year observational study will follow 10,000 adults with diabetes, metabolic disorders, and related conditions like high blood pressure and fatty liver disease. Researchers will collect routine medical data to identify markers of disease severity and activity. The goal is …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Gum disease linked to heart risk marker in new study
Knowledge-focused Not yet recruitingThis study compares levels of oxidized LDL (a type of 'bad' cholesterol linked to heart disease) in the gum fluid of people with advanced gum disease versus those with healthy gums. Researchers aim to better understand the connection between gum inflammation and heart health. The…
Sponsor: shaimaa hamdy • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:15 UTC